Drug Profile
Research programme: ocular therapeutics - Genisphere
Alternative Names: G8-3DNA-Dox; GL-249Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Genisphere
- Class DNA; Immunoconjugates
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Postoperative inflammation
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Postoperative inflammation (Prevention) in USA (Parenteral) (Genisphere website, September 2023)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Postoperative-inflammation(Prevention) in USA (Parenteral, Injection)
- 09 Jun 2016 GL 249 is available for licensing as of 09 Jun 2016. http://www.genisphere.com/about-us